At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 9, 2026 at 09:01 ET
KALA BIO reported preliminary Q3 2026 net loss of approximately $0.8 million, a ~90% reduction from $7.6 million in Q3 2025, with cash of $7.0 million and no debt. The company also announced a strategic pivot to an AI infrastructure platform for biotech, alongside its existing biologics pipeline. No revenue or EPS consensus was available, so no beat/miss rating is assigned.
- Preliminary Q3 2026 net loss of approximately $0.8 million, compared to $7.6 million in Q3 2025
- Nine-month 2026 net loss of approximately $4.0 million, compared to $27.7 million in the same period of 2025
- Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
- Company announced a strategic shift to an on-premises AI infrastructure platform for biotech, alongside its MSC-S biologics pipeline
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access